KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biolife Solutions (BLFS) Research & Development (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Research & Development for 16 consecutive years, with -$67000.0 as the latest value for Q4 2025.

  • Quarterly Research & Development rose 94.62% to -$67000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 59.23% year-over-year, with the annual reading at $7.6 million for FY2025, 59.25% up from the prior year.
  • Research & Development for Q4 2025 was -$67000.0 at Biolife Solutions, down from $2.7 million in the prior quarter.
  • The five-year high for Research & Development was $4.2 million in Q1 2023, with the low at -$5.3 million in Q4 2023.
  • Average Research & Development over 5 years is $2.0 million, with a median of $2.7 million recorded in 2025.
  • The sharpest move saw Research & Development surged 106.16% in 2021, then crashed 167.8% in 2023.
  • Over 5 years, Research & Development stood at $3.6 million in 2021, then plummeted by 154.97% to -$2.0 million in 2022, then plummeted by 167.8% to -$5.3 million in 2023, then skyrocketed by 76.3% to -$1.2 million in 2024, then skyrocketed by 94.62% to -$67000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at -$67000.0, $2.7 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.